News
Orphan drug assessment: is a special approach required?
WHO Cancer R&D Report: Imbalances and Gaps in Clinical Research
Pharmaceutical markets of the CIS countries: results of July 2025 (according to IQVIA)
Rare Disease Evidence Principles (RDEP) - new FDA principles for evaluating orphan drugs
Results of the session "Legal and regulatory space for rare diseases: challenges, approaches, prospects" II CIS Orphan Forum | Moscow, June 27, 2025
WHO presents strategy for transforming paediatric drug system
NICE updates approach to orphan technologies
The CIS Orphan Consortium OMT Working Group has identified priorities
Orphan Drugs 2024: A Review of Progress in the US and Europe
New era in health technology assessment in the EU: Joint Clinical Assessment Regulation comes into force